27 results
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
and the investor. The Engagement Agreement does not give rise to any commitment by the placement agent to purchase any of our securities, and the placement agent
6-K
EX-99.2
ENLV
Enlivex Therapeutics Ltd
11 Apr 24
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
8:13am
of our securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment
6-K
EX-99.1
ENLV
Enlivex Therapeutics Ltd
11 Sep 23
Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
8:00am
their efforts and commitment, and we wish them continued success in their individual paths forward. Our reprioritization is expected to decrease
6-K
EX-99.1
kf7wb
29 Aug 22
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells
8:01am
6-K
EX-99.1
atdg0fyv
30 Sep 21
Annual and Extraordinary General Meeting of Shareholders
8:01am
FWP
h50e4g
10 Feb 21
Free writing prospectus
6:08am
FWP
zdpik l7f
9 Feb 21
Free writing prospectus
5:21pm
6-K
EX-10.1
hl4pza2s o9ofeaqfn
22 Oct 20
Report of Foreign Private Issuer
8:47am
6-K
EX-99.1
hlt9gyvl
19 May 20
Annual and Extraordinary General Meeting of Shareholders
8:04am
424B5
t2ahm g5y5jpljaxp
3 Mar 20
Prospectus supplement for primary offering
5:13pm
424B5
ov27jtqlswg4
26 Feb 20
Prospectus supplement for primary offering
8:23am